Vtv Therapeutics Inc. 8-K Filing
Ticker: VTVT · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vtv Therapeutics Inc. (ticker: VTVT) to the SEC on Dec 19, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market).
How long is this filing?
Vtv Therapeutics Inc.'s 8-K filing is 2 pages with approximately 467 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-12-19 17:10:40
Key Financial Figures
- $0.01 — stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market
Filing Documents
- vtvt-20251219.htm (8-K) — 24KB
- firstamendmenttothesecon.htm (EX-3.1) — 2KB
- firstamendmenttothesecon001.jpg (GRAPHIC) — 109KB
- 0001641489-25-000066.txt ( ) — 292KB
- vtvt-20251219.xsd (EX-101.SCH) — 2KB
- vtvt-20251219_lab.xml (EX-101.LAB) — 22KB
- vtvt-20251219_pre.xml (EX-101.PRE) — 13KB
- vtvt-20251219_htm.xml (XML) — 3KB
03 Amendments to Articles of Incorporation or By-Laws
Item 5.03 Amendments to Articles of Incorporation or By-Laws On December 19, 2025, the Board of Directors of vTv Therapeutics Inc. (the Company) amended Section 2.8 of Article II of the Company's Second Amended and Restated By-Laws to reduce the quorum requirement for any meeting of stockholders to 33.4%. A copy of the First Amendment to the Second Amended and Restated By-Laws is attached to this Form 8-K as Exhibit 3.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 3.1 First Amendment to the Second Amended and Restated By-Laws of vTv Therapeutics Inc. 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President and Chief Executive Officer Dated: December 19, 2025